4
Changes in Ownership
Contineum Therapeutics, Inc. Filed Acc 0001437749-26-004122
Chief Scientific Officer sold 400 shares at $16.00 ($6,400)
- Chief Scientific Officer acquired 400 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lorrain Daniel S. · Chief Scientific Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-11 | Exercise or conversion : show line 1 in the form 10b5-1 | +400 | $1.01 | $404 | 156,452 | D |
| 2026-02-11 | Sale : show line 2 in the form 10b5-1 | −400 | $16.00 | $6,400 | 156,052 | D |
| Open-market sales · 400 sh · avg $16.00 · $6,400 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-02-11 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −400 | 75,530 | D |
Loading xslF345X05/rdgdoc.xml…